Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 13/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.59 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efinaconazole SCHEMBL8376515 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL300738 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL18289601 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL29858056 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL20259496 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL18289604 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL20017139 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375955 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375839 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375117 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106918672-B | Method for measuring related substances in efinaconazole raw material medicine and preparation thereof by using HPLC | 中美华世通生物医药科技（武汉）有限公司 | 2021-02-09 | — | — | CN | claimed |
| US-10125115-B2 | Process for the preparation of efinaconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-11-13 | — | — | US | claimed |
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-06-14 | — | — | US | claimed |
| WO-2016193917-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-12-08 | — | — | WO | claimed |
| CN-116589447-A | Chemical-enzymatic process synthesis method of efroconazole | 浙江工业大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-110433291-B | Stable ifetroconazol compositions | 博世健康爱尔兰有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3628668-B1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMA CO LTD (JP) | 2023-02-22 | — | — | EP | disclosed |
| CN-110770220-B | Preparation and purification method of efinaconazole | 科研制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3885341-A1 | PREPARATION METHOD FOR EFINACONAZOLE | Viwit Pharmaceutical Co., Ltd. (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20210154215-A1 | Antifungal Cuticle Oil Composition | ZENVISION PHARMA LLP (IN) | 2021-05-27 | — | — | US | disclosed |
| EP-3556368-B1 | ONYCHOMYCOSIS THERAPEUTIC AGENT | KANEKA CORP (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-9617241-B2 | Intermediate compounds and process for the preparation of efinaconazole | MAPI PHARMA LTD. (IL) | 2017-04-11 | — | — | US | disclosed |
| US-20160355500-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF EFINACONAZOLE | MAPI PHARMA LTD. (IL) | 2016-12-08 | — | — | US | disclosed |
| WO-2016079728-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF EFINACONAZOLE | MAPI PHARMA LTD. (IL) | 2016-05-26 | — | — | WO | disclosed |
| US-5962476-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5716969-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0698606-B1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMA CO LTD (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5620994-A | FUNGICIDES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0698606-A1 | AZOLYLAMINE DERIVATIVE | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1996-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | CYP3A43, CYP3A5, CYP51A1 | CYP3A4 4/4885CYP2C9 13/4885CYP2C19 12/4885 |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | CYP7A1, CYP7B1, CYP27A1 | CYP3A4 45/4885CYP2C9 88/4885CYP2C19 100/4885 |
| US-20210154215-A1 | Antifungal Cuticle Oil Composition | NACA, POLR1C, CUTA | CYP3A4 957/4885CYP2C9 106/4885CYP2C19 135/4885 |
| US-10125115-B2 | Process for the preparation of efinaconazole | CYP3A43, CYP3A5, CYP51A1 | CYP3A4 4/4885CYP2C9 13/4885CYP2C19 12/4885 |
| US-20160355500-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF EFINACONAZOLE | CYP2E1, CYP3A4, CYP4B1 | CYP3A4 2/4885CYP2C9 41/4885CYP2C19 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.